BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24637943)

  • 1. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
    Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
    Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.
    Yuan H; Huang Z; Yang G; Lv H; Sang H; Yao Y
    J Int Med Res; 2008; 36(6):1354-62. PubMed ID: 19094446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
    Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
    J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
    Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
    Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
    Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
    Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.
    Duricova J; Perinova I; Jurckova N; Jeziskova I; Kacirova I; Grundmann M
    Bratisl Lek Listy; 2013; 114(4):206-12. PubMed ID: 23514553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
    Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
    Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk.
    Chen L; Xiao T; Chen L; Xie S; Deng M; Wu D
    Am J Med Sci; 2018 Mar; 355(3):235-239. PubMed ID: 29549925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
    Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
    Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
    Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
    Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
    Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
    Lymperopoulos A; McCrink KA; Brill A
    Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.